TAYSHA GENE THERAPIES INC
TSHANASDAQTrading Snapshot
- Day Range
- $6.34 – $6.51
- 52-Week Range
- $2.69 – $7.30
- Volume
- $3.36B
- Avg Volume
- $2.64B
- Shares Outstanding
- 319.8M
- Next Earnings
- Oct 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 208.5x
- EPS (TTM)
- $-0.38
- Dividend Yield
- —
Why Investors Own TSHA
- ✓High-growth profile — revenue up +38.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About TAYSHA GENE THERAPIES INC
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsHayleigh Collins - Director of Corporate...
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now. On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten public offering of 32.5 million of its common stock, priced at $6 per share. The offering also involved prepaid warrants to buy 833,333 shares […]